Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Day One Biopharmaceuticals Inc (DAWN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DAWN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23.38
1 Year Target Price $23.38
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.03% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 640.20M USD | Price to earnings Ratio - | 1Y Target Price 23.38 |
Price to earnings Ratio - | 1Y Target Price 23.38 | ||
Volume (30-day avg) 8 | Beta -1.27 | 52 Weeks Range 5.63 - 16.76 | Updated Date 08/15/2025 |
52 Weeks Range 5.63 - 16.76 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.351 | Actual -0.29 |
Profitability
Profit Margin -50.63% | Operating Margin (TTM) -103.14% |
Management Effectiveness
Return on Assets (TTM) -15.19% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 190099581 | Price to Sales(TTM) 3.41 |
Enterprise Value 190099581 | Price to Sales(TTM) 3.41 | ||
Enterprise Value to Revenue 1.01 | Enterprise Value to EBITDA -7.18 | Shares Outstanding 102432000 | Shares Floating 73010409 |
Shares Outstanding 102432000 | Shares Floating 73010409 | ||
Percent Insiders 16.87 | Percent Institutions 98.47 |
Upturn AI SWOT
Day One Biopharmaceuticals Inc
Company Overview
History and Background
Day One Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for cancers affecting children and adolescents. Founded in 2018, it focuses on addressing unmet needs in pediatric oncology.
Core Business Areas
- Oncology Drug Development: Focused on discovering, developing, and commercializing new therapies for pediatric cancers.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team includes key executives focused on research, development, and commercialization. The organizational structure is typical of a biotech company, with departments dedicated to research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Tovorafenib: A highly selective type II RAF kinase inhibitor, specifically designed to target pediatric low-grade glioma (pLGG). Tovorafenib recently received accelerated approval from the FDA for BRAF-altered pLGG. Currently, Tovorafenib is the only drug in the market specifically approved for BRAF-altered pLGG, giving it 100% market share in that very specific indication. Competitors focusing on broader cancer treatments may include companies with drugs targeting RAF kinases, but none are specifically indicated for BRAF-altered pLGG.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant returns on investment. The oncology segment, particularly pediatric oncology, presents significant unmet medical needs.
Positioning
Day One Biopharmaceuticals is positioned as a leader in developing targeted therapies for pediatric cancers, particularly in areas with high unmet need. Their competitive advantage lies in their focus on specific genetic mutations and their pipeline of targeted therapies.
Total Addressable Market (TAM)
The global pediatric cancer therapeutics market is estimated to be worth several billion dollars. Day One's focus on specific genetic mutations allows them to address a targeted segment of this market, potentially capturing a significant share. The specific TAM for BRAF-altered pLGG is smaller but represents a significant opportunity given the lack of existing treatments.
Upturn SWOT Analysis
Strengths
- Specialized focus on pediatric oncology
- Targeted therapies with potential for high efficacy
- Strong leadership team
- FDA accelerated approval for Tovorafenib
- Proprietary drug development platform
Weaknesses
- Limited product pipeline
- Reliance on clinical trial outcomes
- High research and development costs
- Dependent on successful commercialization of Tovorafenib
Opportunities
- Expansion of product pipeline through in-licensing or acquisition
- Partnerships with other pharmaceutical companies
- Expansion into new geographic markets
- Further clinical trials to expand label for Tovorafenib
- Potential for breakthrough therapy designations
Threats
- Clinical trial failures
- Regulatory challenges
- Competition from larger pharmaceutical companies
- Patent expirations
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- GILD
- MRTX
- ARRY
Competitive Landscape
Day One's competitive advantage lies in its specific focus on pediatric oncology and targeted therapies. However, it faces competition from larger pharmaceutical companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancements in clinical trials and pipeline development.
Future Projections: Future growth is dependent on successful commercialization of Tovorafenib and continued progress in the pipeline. Analyst estimates project significant revenue growth in the coming years.
Recent Initiatives: Focus on commercializing Tovorafenib, expanding the product pipeline through in-licensing or acquisition, and conducting further clinical trials.
Summary
Day One Biopharmaceuticals is a promising company focused on pediatric oncology, particularly in areas with high unmet medical need. The recent FDA approval of Tovorafenib represents a significant milestone, providing a commercial opportunity and potential for future growth. However, the company remains dependent on the successful commercialization of Tovorafenib and continued pipeline development. Investors should monitor clinical trial results, regulatory developments, and competitive dynamics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Press Releases
- FDA Website
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Day One Biopharmaceuticals Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-27 | CEO, President & Director Dr. Jeremy Bender M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 182 | Website https://dayonebio.com |
Full time employees 182 | Website https://dayonebio.com | ||
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.